BioCentury | Apr 13, 2021
Product Development

FDA requests more data from Provention; plus Iterum, Seagen-Genmab, Pfizer and Gilead

...Xeljanz/Xeljanz XR tofacitinib to treat active ankylosing spondylitis by three months to 3Q21. Pfizer markets Xeljanz...
...Janus kinase-1TROP2 (TACSTD2) (EGP-1)- Tumor-associated calcium signal transducer 2 BC Staff Sulopenem etzadroxil-probenecid (PF-03709270) HuMax-TF-ADC, tisotumab vedotin abrocitinib (PF-04965842) Xeljanz...
BioCentury | Jan 27, 2021
Regulation

Jan. 27 Quick Takes: European label expansions for Rinvoq, Keytruda; plus GBT, BeiGene and Pfizer

...billion in milestones, plus royalties. Xeljanz misses in post-marketing study for rheumatoid arthritis Pfizer Inc. (NYSE:PFE) said Xeljanz...
BioCentury | Oct 13, 2020
Product Development

Gilead’s Jyseleca has a leg up over BMS’s Zeposia in biologic-experienced UC patients

...with Jyseleca showing an edge in biologic-experienced patients. Xeljanz...
...Xeljanz and marketed biologics for UC. For Xeljanz, Pfizer...
...placebo.Jyseleca is more selective for JAK-1 than Pfizer’s Xeljanz...
BioCentury | Aug 19, 2020
Product Development

Filgotinib setback a blow to building franchise around Gilead-Galapagos therapy

...market since 2018; it posted $284.4 million in first half sales. The first to be approved, Xeljanz...
...gave the therapy a best-in-class safety profile when paired with its competitive efficacy data. Olumiant, Rinvoq and Xeljanz...
BioCentury | Apr 9, 2020
Product Development

Pfizer’s COVID-19 push: antiviral candidate identified as anti-inflammatory Xeljanz starts trial

...lead antiviral candidate and announced the planned start of a Phase II study of anti-inflammatory Xeljanz...
...determine the 3CLpro inhibitor’s suitability for IV administration. The investigator-initiated trial of oral JAK inhibitor Xeljanz...
...Coronavirus 3C-like proteinase JAK - Janus kinase Sandi Wong, Assistant Editor Jaquinus, Xeljanz, tofacitinib (CP-690,550, CP-690550, tasocitinib) Liverpool...
BioCentury | Jan 28, 2020
Company News

Bourla chooses BD over buybacks in 2020

...by sales of breast cancer drug Ibrance palbociclib, cardiovascular therapy Eliquis apixaban and autoimmune therapy Xeljanz...
...CDK4/6 inhibitors in the U.S. Eliquis sales grew 23% to $4.2 billion in 2019, and Xeljanz...
BioCentury | Aug 16, 2019
Company News

Rinvoq approval bolsters AbbVie's autoimmune portfolio

...month at an annual wholesale acquisition cost (WAC) of $59,000. The WAC of autoimmune drug Xeljanz...
BioCentury | Jul 26, 2019
Company News

July 26 Company Quick Takes: Lexicon hit by Phase III miss, scuttled deal; plus Xeljanz, Shield, Galapagos, Amarin and more

...warning to Xeljanz label FDA added a boxed warning to the label for autoimmune drug Xeljanz...
...trial to treat rheumatoid arthritis (see "Pfizer Reports Increase in Lung Clots, Death with High-Dose Xeljanz"...
...maltol (ST10) Jaquinus, Xeljanz, tofacitinib (CP-690,550, CP-690550, tasocitinib) Vascepa (amr101, icosapent ethyl, miraxion, AMR-101, LAX-101) Xarelto, rivaroxaban (BAY 59-7939) Xeljanz...
BioCentury | Jul 3, 2019
Clinical News

July 3 Clinical Quick Takes: GSK starts Phase III otilimab RA program; plus Unum, Xofluza and more

...trials and a long-term extension study, will include head-to-head comparisons of otilimab against pan-JAK inhibitor Xeljanz...
BioCentury | Feb 22, 2019
Clinical News

Pfizer reports increase in lung clots, death with high-dose Xeljanz in postmarket study

...pulmonary embolisms and deaths among rheumatoid arthritis patients receiving the twice-daily 10 mg dose of Xeljanz...
...Xeljanz arm compared with the twice-daily 5 mg Xeljanz arm and the TNFα inhibitor arms. Xeljanz...
...cardiovascular events (MACE) Status: Postmarketing trial data Milestone: NA Elizabeth S. Eaton Jaquinus, Xeljanz, tofacitinib (CP-690,550, CP-690550, tasocitinib) Pfizer...
Items per page:
1 - 10 of 147